Children with severe asthma have a premature loss of lung function during the adolescent years that is associated with increased symptom frequency and greater allergic sensitization during childhood.
To the Editor
Severe asthma in children is heterogeneous disorder associated with extreme morbidity despite treatment with high doses of inhaled corticosteroids (ICS). We previously reported the phenotypic features of children with mild-to-moderate and severe asthma (mean age, 10 years) enrolled in the National Heart, Lung and Blood Institute's (NHLBI) Severe Asthma Research Program (SARP) at Emory University (1) . Similar to adults with severe asthma (2) , children with severe asthma were characterized by baseline airflow limitation that was not completely reversed with bronchodilation (1). However, the magnitude of airflow limitation was significantly less in children with severe asthma (FEV 1 : 81% predicted, FEV 1 /FVC: 0.74) as compared to adults (FEV 1 : 62% predicted, FEV 1 /FVC: 0.65) (2). These findings raise important questions about the stability of the severe asthma phenotype in children and the critical developmental time frame during which loss of lung function occurs. While the answers to these questions are not entirely clear, longitudinal studies have shown that children with more severe, frequent symptoms have ongoing airflow limitation and more severe asthma throughout adulthood (3) (4) (5) . Using longitudinal follow-up data from children previously characterized in the NHLBI SARP, we report that children with severe asthma have a premature loss of lung function during the adolescent years that is associated with an increased frequency of wheezing and asthma symptoms and greater allergic sensitization during childhood.
Children with mild-to-moderate (n = 12, 67% male) and severe (n = 28, 57% male) asthma previously characterized in the NHLBI SARP at Emory University between 2004-2007 were re-evaluated between 2008-2010. At the follow-up visit, children repeated questionnaires and underwent severity classification assignment and spirometry with maximal bronchodilator reversibility testing with up to 8 inhalations of albuterol sulfate (90 μg/inhalation) as previously described (1) . The differences between the initial and follow-up spirometric data were calculated and divided by the number of years between study visits. Multivariate logistic regression models were used to determine the association between characterization variables and changes in lung function.
The mean age at the initial evaluation and follow-up visit was 11 ± 3 and 14 ± 3 years, respectively, with a mean visit interval of 3 ± 2 years. There were no changes in subject severity classification between the initial characterization visit and the follow-up assessment. Demographic features were also similar to our previous report (1) . Children with severe asthma had a higher frequency of daily symptoms (46 vs. 8%, p = 0.030) and hospitalization within the previous year (32 vs. 0%, p = 0.037). This was despite higher daily doses of ICS (744 ± 328 vs. 365 ± 280 μg fluticasone/day, p < 0.001) and a higher frequency of controller medication use (montelukast: 100% vs. 75%, p = 0.029; long-acting beta agonists: 93 vs. 17%, p < 0.001). Lung function percent predicted values also remained significantly lower in children with severe versus mild-to-moderate asthma at the follow-up assessment (FEV 1 : 78 ± 20 vs. 102 ± 15%, p = 0.001; FVC: 96 ± 19 vs. 105 ± 18%, p = 0.168; FEV 1 /FVC: 82 ± 13 vs. 97 ± 9%, p < 0.001).
The average yearly change in FEV 1 and FVC (in liters) and FEV 1 /FVC (%) for each group is shown in Figure 1 . Although FEV 1 and FVC increased in both groups with age, the average yearly increase in FEV 1 and FVC was significantly less in children with severe asthma. These findings were apparent before ( Figure 1A, 1C ) and after maximal bronchodilation (Figure 1B, 1D ) and persisted after age-appropriate lung function reference equations (that account for variations in height during the adolescent growth spurt) were applied to the data (6) . Similarly, the FEV 1 /FVC percent predicted remained lower in children with severe asthma ( Figure 1E ) and even worsened in a subset ( Figure 1F ). Of further note, post-bronchodilator FEV 1 percent predicted values declined in 46% of the children with severe asthma between the follow-up interval and 29% of these children had post-bronchodilator FEV 1 declines of more than 1% per year ( Figure 2 ). Using multivariate models, race, gender, and healthcare utilization history (e.g., prior hospitalizations, intubations and emergency room visits) were not associated with significant declines in FEV 1 in the severe asthma group. However, daily asthma symptoms including coughing or wheezing (odds ratio [OR], 3.66; 95% CI, 1.29-10.34, p = 0.015) and the number of aeroallergen skin prick responses (OR, 1.29; 95% CI, 1.05-1.58, p = 0.011) at the initial evaluation were strong predictors of post-bronchodilator FEV 1 declines of more than 1% per year.
These results support the hypothesis that progressive airflow limitation is a feature of severe asthma in children. Although progressive airflow limitation was previously observed in a subset of children with mild-to-moderate asthma enrolled in the Childhood Asthma Management Research Program, not all children in that subset had clinical evidence of more severe disease. Rather, the average post-bronchodilator FEV 1 in that subgroup was 108% at baseline and 96% at the completion of the study (7, 8) . However, further analysis revealed significantly lower lung function, greater allergic sensitization and increased asthma morbidity in children with persistent versus remitting disease (9) , similar to what we report here. Indeed, our sample of children with severe asthma was characterized by a high degree of morbidity and substantial airflow limitation that persisted throughout the follow-up interval, although the magnitude of airflow limitation in these children was significantly less than what is commonly seen in adults with severe asthma (2) . The fact that airflow limitation persisted and even worsened in many children with severe asthma despite high doses of ICS and other asthma controller medications is intriguing and raises important questions about the corticosteroid sensitivity of this sample. Whether this loss of lung function represents a reduction in lung growth velocity or progression of airway remodeling is also unclear and warrants further study. Calculated yearly change in post-bronchodilator FEV 1 percent predicted values in children with mild-to-moderate and severe asthma. Lines represent the mean. *p < 0.05
